Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter for 2016 Approvals

Posted by Matt Breese on Jan 5, 2017

Find me on:

In our weekly Trends that Matter series, we provide engaging infographics from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured pharma topic is drug approval. In 2016, 22 new drugs were approved by the FDA. 

The rate of drug approvals slowed down from the 2015 level. 

"Last year turned out to be a disappointing one for new drug approvals with the U.S. Food and Drug Administration clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015's tally of 45," according to Reuters.

Many pharmaceutical experts believe this decreased approval rate is simply due to the schedule of applications. According to FierceBiotech:

"The key culprit looks to be timing: multiple drugs slated for 2016 approval—including AstraZeneca’s Tagrisso, Genentech’s Alecensa and Pfizer’s Ibrance—bagged accelerated approvals in 2015, boosting that year’s crop to 45, a high topped only by the 53 approved in 1996."

View the infographic below, created by Reuters to see the change in FDA drug approvals over time.

FDA Drug Approvals in 2016.png


Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter

Topics: Industry Trends